A citation-based method for searching scientific literature


List of co-cited articles
8 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation.
Laween Uthman, Antonius Baartscheer, Boris Bleijlevens, Cees A Schumacher, Jan W T Fiolet, Anneke Koeman, Milena Jancev, Markus W Hollmann, Nina C Weber, Ruben Coronel,[...]. Diabetologia 2018
132
100

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Mikhail Kosiborod, Matthew A Cavender, Alex Z Fu, John P Wilding, Kamlesh Khunti, Reinhard W Holl, Anna Norhammar, Kåre I Birkeland, Marit Eika Jørgensen, Marcus Thuresson,[...]. Circulation 2017
383
100

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.
David Fitchett, Bernard Zinman, Christoph Wanner, John M Lachin, Stefan Hantel, Afshin Salsali, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Silvio E Inzucchi. Eur Heart J 2016
494
100

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
764
100

Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project.
Suzanne V Arnold, Silvio E Inzucchi, Fengming Tang, Darren K McGuire, Sanjeev N Mehta, Thomas M Maddox, Abhinav Goyal, Laurence S Sperling, Daniel Einhorn, Nathan D Wong,[...]. Eur J Prev Cardiol 2017
50
100

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
136
100

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
100

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
100

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
50

Unrecognised cardiovascular disease in type 2 diabetes: is it time to act earlier?
Guntram Schernthaner, Chaim Lotan, Elina Baltadzhieva-Trendafilova, Jonas Ceponis, Martin Clodi, Kristine Ducena, Eva Goncalvesova, Cristian Guja, Marek Honka, Andrej Janež,[...]. Cardiovasc Diabetol 2018
7
50

Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus.
G Reach, V Pechtner, R Gentilella, A Corcos, A Ceriello. Diabetes Metab 2017
69
50



Clinical Inertia in Type 2 Diabetes Management: Evidence From a Large, Real-World Data Set.
Kevin M Pantalone, Anita D Misra-Hebert, Todd M Hobbs, Xinge Ji, Sheldon X Kong, Alex Milinovich, Wayne Weng, Janine Bauman, Rahul Ganguly, Bartolome Burguera,[...]. Diabetes Care 2018
31
50

The cost effectiveness of REACH-HF and home-based cardiac rehabilitation compared with the usual medical care for heart failure with reduced ejection fraction: A decision model-based analysis.
Rod S Taylor, Susannah Sadler, Hasnain M Dalal, Fiona C Warren, Kate Jolly, Russell C Davis, Patrick Doherty, Jackie Miles, Colin Greaves, Jennifer Wingham,[...]. Eur J Prev Cardiol 2019
11
50



Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis.
Marco Castellana, Filippo Procino, Rodolfo Sardone, Pierpaolo Trimboli, Gianluigi Giannelli. Cardiovasc Diabetol 2020
5
50

Comments on the 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases.
Anders Jorsal, Frederik Persson, Jens Meldgaard Bruun. Eur Heart J 2020
7
50



Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis.
Shintaro Sakurai, Teruo Jojima, Toshie Iijima, Takuya Tomaru, Isao Usui, Yoshimasa Aso. J Diabetes Complications 2020
1
100

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
Mikhail Kosiborod, Carolyn S P Lam, Shun Kohsaka, Dae Jung Kim, Avraham Karasik, Jonathan Shaw, Navdeep Tangri, Su-Yen Goh, Marcus Thuresson, Hungta Chen,[...]. J Am Coll Cardiol 2018
171
50

Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis.
G Schernthaner, A H Barnett, D J Betteridge, R Carmena, A Ceriello, B Charbonnel, M Hanefeld, R Lehmann, M T Malecki, R Nesto,[...]. Diabetologia 2010
65
50

Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Aidin Rawshani, Araz Rawshani, Stefan Franzén, Naveed Sattar, Björn Eliasson, Ann-Marie Svensson, Björn Zethelius, Mervete Miftaraj, Darren K McGuire, Annika Rosengren,[...]. N Engl J Med 2018
293
50

Addressing Clinical Inertia in Type 2 Diabetes Mellitus: A Review.
Jennifer Okemah, John Peng, Manuel Quiñones. Adv Ther 2018
38
50

Physicians' perceptions of reimbursement as a barrier to comprehensive diabetes care.
Alyssa Pozniak, Lois Olinger, Victoria Shier. Am Health Drug Benefits 2010
6
50

Weight Management in Patients with Type 2 Diabetes: a Multidisciplinary Real-world Approach.
Osama Hamdy, Sahar Ashrafzadeh, Adham Mottalib. Curr Diab Rep 2018
6
50

DOES CLINICAL INERTIA VARY BY PERSONALIZED A1C GOAL? A STUDY OF PREDICTORS AND PREVALENCE OF CLINICAL INERTIA IN A U.S. MANAGED-CARE SETTING.
Jay Lin, Steve Zhou, Wenhui Wei, Chunshen Pan, Melissa Lingohr-Smith, Philip Levin. Endocr Pract 2016
27
50


The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care.
Elisabetta Patorno, Mehdi Najafzadeh, Ajinkya Pawar, Jessica M Franklin, Anouk Déruaz-Luyet, Kimberly G Brodovicz, Adrian J Santiago Ortiz, Lily G Bessette, Martin Kulldorff, Sebastian Schneeweiss. Endocrinol Diabetes Metab 2019
2
50

Impact of Cardio-Renal-Metabolic Comorbidities on Cardiovascular Outcomes and Mortality in Type 2 Diabetes Mellitus.
David Z I Cherney, Enrico Repetto, David C Wheeler, Suzanne V Arnold, Sharon MacLachlan, Philip R Hunt, Hungta Chen, Jiten Vora, Mikhail Kosiborod. Am J Nephrol 2020
3
50

Trends in antidiabetic drug utilization and expenditure in Denmark: A 22-year nationwide study.
Camilla Bang, Martin B Mortensen, Kasper G Lauridsen, Jens M Bruun. Diabetes Obes Metab 2020
3
50

Cost-of-illness studies in heart failure: a systematic review 2004-2016.
Wladimir Lesyuk, Christine Kriza, Peter Kolominsky-Rabas. BMC Cardiovasc Disord 2018
63
50

Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study.
Jakob S Knudsen, Lisbeth M Baggesen, Maria Lajer, Larisa Nurkanovic, Anastasia Ustyugova, Henrik T Sørensen, Reimar W Thomsen. PLoS One 2020
5
50


Estimating the financial cost of chronic kidney disease to the NHS in England.
Marion Kerr, Benjamin Bray, James Medcalf, Donal J O'Donoghue, Beverley Matthews. Nephrol Dial Transplant 2012
164
50

Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study.
Björn Pasternak, Viktor Wintzell, Mads Melbye, Björn Eliasson, Ann-Marie Svensson, Stefan Franzén, Soffia Gudbjörnsdottir, Kristian Hveem, Christian Jonasson, Henrik Svanström,[...]. BMJ 2020
8
50

Clinical inertia in individualising care for diabetes: is there time to do more in type 2 diabetes?
William David Strain, Matthias Blüher, Païvi Paldánius. Diabetes Ther 2014
35
50

A Big Win for Diabetic Kidney Disease: CREDENCE.
David Z I Cherney, Ayodele Odutayo, Subodh Verma. Cell Metab 2019
8
50

Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial.
Pedro Monteiro, Richard M Bergenstal, Elvira Toural, Silvio E Inzucchi, Bernard Zinman, Stefan Hantel, Sanja Giljanovic Kiš, Stefan Kaspers, Jyothis T George, David Fitchett. Age Ageing 2019
15
50

Knowledge of risk factors for diabetes or cardiovascular disease (CVD) is poor among individuals with risk factors for CVD.
Monique F Kilkenny, Libby Dunstan, Doreen Busingye, Tara Purvis, Megan Reyneke, Mary Orgill, Dominique A Cadilhac. PLoS One 2017
6
50

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Donna K Arnett, Roger S Blumenthal, Michelle A Albert, Andrew B Buroker, Zachary D Goldberger, Ellen J Hahn, Cheryl Dennison Himmelfarb, Amit Khera, Donald Lloyd-Jones, J William McEvoy,[...]. J Am Coll Cardiol 2019
206
50

Estimated glomerular filtration rate, albuminuria and mortality in type 2 diabetes: the Casale Monferrato study.
G Bruno, F Merletti, G Bargero, G Novelli, D Melis, A Soddu, M Perotto, G Pagano, P Cavallo-Perin. Diabetologia 2007
74
50


Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
50

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
Rury R Holman, M Angelyn Bethel, Robert J Mentz, Vivian P Thompson, Yuliya Lokhnygina, John B Buse, Juliana C Chan, Jasmine Choi, Stephanie M Gustavson, Nayyar Iqbal,[...]. N Engl J Med 2017
659
50

Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats.
Alana Aragón-Herrera, Sandra Feijóo-Bandín, Manuel Otero Santiago, Luis Barral, Manuel Campos-Toimil, José Gil-Longo, Thiago M Costa Pereira, Tomás García-Caballero, Santiago Rodríguez-Segade, Javier Rodríguez,[...]. Biochem Pharmacol 2019
24
50

GPs' understanding of the benefits and harms of treatments for long-term conditions: an online survey.
Julian Stephen Treadwell, Geoff Wong, Coral Milburn-Curtis, Benjamin Feakins, Trisha Greenhalgh. BJGP Open 2020
4
50

United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal disease.
Allan J Collins, Robert N Foley, David T Gilbertson, Shu-Cheng Chen. Kidney Int Suppl (2011) 2015
150
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.